Who owns Tarsus Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of TARS from SEC Form 13F filings across 255 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 255 institutions disclosed 52.3M shares of Tarsus Pharmaceuticals, Inc. worth $4.10B — about 112.6% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
255
13F holders
$4.10B
value, 2026 filers
112.6%
of shares outstanding (52.3M sh)
46
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of TARS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.9M | $303.9M | 0.0% | 8.3% | +0.3% |
| 2 | Deep Track Capital, LP | 3.8M | $299.3M | 4.9% | 8.2% | +3.8% |
| 3 | RTW INVESTMENTS, LP | 3.5M | $273.9M | 2.8% | 7.5% | +3.8% |
| 4 | FMR LLC | 3.3M | $250.4M | 0.0% | 7.1% | +386.4% |
| 5 | Janus Henderson Group Ltd.NEW | 2.9M | $226.4M | 0.1% | 6.2% | new |
| 6 | Paradigm Biocapital Advisors LP | 2.3M | $180.9M | 3.6% | 5% | -17.1% |
| 7 | Vestal Point Capital, LP | 2.0M | $159.9M | 4.1% | 4.4% | +93.7% |
| 8 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $150.7M | 6.9% | 4.1% | +22.3% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $147.7M | 0.0% | 4% | +4.8% |
| 10 | MORGAN STANLEY | 1.7M | $134.5M | 0.0% | 3.7% | -6.4% |
| 11 | JENNISON ASSOCIATES LLC | 1.3M | $103.5M | 0.1% | 2.8% | -20.8% |
| 12 | BANK OF AMERICA CORP /DE/ | 1.2M | $92.7M | 0.0% | 2.5% | -1.2% |
| 13 | STATE STREET CORP | 1.1M | $86.8M | 0.0% | 2.4% | +2.9% |
| 14 | Bain Capital Life Sciences Investors, LLCNEW | 1.1M | $86.2M | 5.8% | 2.4% | new |
| 15 | MILLENNIUM MANAGEMENT LLC | 1.1M | $85.5M | 0.0% | 2.4% | -23.4% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $83.1M | 0.0% | 2.3% | -4.5% |
| 17 | Invesco Ltd. | 879,788 | $69.2M | 0.0% | 1.9% | +12.0% |
| 18 | GOLDMAN SACHS GROUP INC | 816,233 | $64.2M | 0.0% | 1.8% | +9.9% |
| 19 | Driehaus Capital Management LLC | 793,265 | $62.4M | 0.4% | 1.7% | +149.8% |
| 20 | Frazier Life Sciences Management, L.P. | 720,338 | $56.6M | 1.4% | 1.6% | -1.1% |
| 21 | Balyasny Asset Management L.P.NEW | 616,404 | $48.5M | 0.1% | 1.3% | new |
| 22 | Assenagon Asset Management S.A. | 615,974 | $48.4M | 0.0% | 1.3% | -35.0% |
| 23 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 547,856 | $43.1M | 0.0% | 1.2% | -9.8% |
| 24 | Aberdeen Group plcNEW | 505,591 | $39.7M | 0.1% | 1.1% | new |
| 25 | UBS Group AG | 471,978 | $37.1M | 0.0% | 1% | +541.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.